Last reviewed · How we verify
NCT07485920
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
Phase 4 trial testing Tislelizumab and nintedanib in Limited-stage Small Cell Lung Cancer (LS-SCLC) in 20 participants. Not yet recruiting.
10 December 2028
Quick facts
| Lead sponsor | The Affiliated Hospital of Qingdao University |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 May 2026 |
| Primary completion | 10 December 2028 |
| Estimated completion | 31 January 2030 |
| Sites | 6 locations across China |
Drugs / interventions tested
- Tislelizumab and nintedanib — full drug profile →
Conditions studied
- Limited-stage Small Cell Lung Cancer (LS-SCLC) — all drugs for Limited-stage Small Cell Lung Cancer (LS-SCLC) →
Sponsor
The Affiliated Hospital of Qingdao University
Who can join
18 and older, any sex, with Limited-stage Small Cell Lung Cancer (LS-SCLC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of tislelizumab combined with nintedanib as consolidation therapy for patients with limited-stage small cell lung cancer after concurrent chemoradiotherapy, and to explore the prognostic markers related to the therapeutic effect.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07485920
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Limited-stage Small Cell Lung Cancer (LS-SCLC)
Currently open trials in the same condition.
- NCT07091305 — A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limite · Phase 2 · active not recruiting
- NCT06869239 — Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-om · recruiting
- NCT06719700 — Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung · Phase 2 · recruiting
- NCT06095583 — Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited · Phase 3 · recruiting
Other The Affiliated Hospital of Qingdao University trials
Trials by the same sponsor.
- NCT07465861 — Bed Rest Duration and Outcomes in Endoscopic Skull Base Reconstruction · NA · not yet recruiting
- NCT07453771 — Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma · NA · not yet recruiting
- NCT07404709 — Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Ste · Phase 1, PHASE2 · not yet recruiting
- NCT07167342 — The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma · Phase 4 · not yet recruiting
- NCT07152886 — The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07485920 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Qingdao University
- Last refreshed: 20 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07485920.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing